Lilly Initiates Phase 2 Trial for Novel Non-Opioid Pain Therapy CFTX-1554
核心洞察
Eli Lilly has dosed the first patients in a Phase 2a clinical trial evaluating CFTX-1554, a novel angiotensin II type 2 receptor antagonist for chronic pain treatment.
The compound represents a non-opioid approach to pain management that aims to avoid centrally mediated side effects such as addiction and sedation.
CFTX-1554 was discovered by Confo Therapeutics using their proprietary GPCR (搜索)-targeting platform and is being developed under a licensing agreement worth up to $590 million in potential milestone payments.
Eli Lilly and Company has initiated dosing in a Phase 2a clinical trial for CFTX-1554, a novel non-opioid pain therapy targeting the angiotensin II type 2 receptor (AT2R (搜索)). The study will evaluate the efficacy, safety and tolerability of the compound in patients with chronic pain, marking a significant milestone for both Lilly and partner Confo Therapeutics.
Novel Mechanism Addresses Unmet Medical Need
CFTX-1554 represents a non-opioid approach to chronic pain management designed to avoid centrally mediated side effects such as addiction and sedation. The compound functions as an antagonist of AT2R (搜索), which has been clinically validated as a target for peripheral pain treatment.
Current standard-of-care therapies for chronic pain provide incomplete pain relief and are often constrained by serious side effects and the potential for abuse. Patients living with these debilitating conditions remain in urgent need of novel pain management options that are efficacious, well-tolerated and can improve quality of life.
Platform Technology Milestone
The Phase 2 initiation represents a pivotal achievement for Confo Therapeutics, as CFTX-1554 is the first candidate discovered using the company's proprietary technology platform to advance into Phase 2 clinical development. Confo specializes in developing medicines targeting G-protein coupled receptors (GPCRs) using conformation-specific ConfoBodies® to promote GPCRs into functionally relevant states.
"The initiation of this study marks a pivotal milestone in Confo's evolution as the first candidate discovered using our proprietary technology has moved into a Phase 2 clinical trial," said Cedric Ververken, CEO of Confo Therapeutics. "We continue to be impressed by Lilly's expertise and commitment in progressing CFTX-1554 and we are delighted with the team's collaborative approach to our valued partnership."
Substantial Licensing Agreement
The development of CFTX-1554 is proceeding under a worldwide licensing agreement between Confo and Lilly announced on March 2, 2023. Under the terms of the agreement, Confo received a $40 million upfront payment from Lilly and is eligible to receive up to $590 million in potential milestone payments per program and tiered royalties.
The agreement also includes provisions for further development of Confo's existing therapeutic antibody candidates targeting the same receptor. Confo maintains a co-investment option to participate in the funding of future development programs after clinical proof-of-concept for additional royalties.
Clinical Development Progress
CFTX-1554 previously completed a Phase 1 first-in-human clinical study (ClinicalTrials.gov Identifier: NCT05260658), demonstrating the compound's progression through early-stage clinical development. The compound was discovered using Confo's proprietary discovery platform, which employs conformation-specific ConfoBodies® to identify small molecules and antibodies with desired pharmacological properties.
The Belgian biotechnology company is building a pipeline of product candidates focused on transforming therapeutic outcomes for patients, with particular emphasis on metabolic and endocrine diseases. Confo Therapeutics is headquartered in Ghent, Belgium, and is led by a team of experienced industry experts with extensive knowledge in GPCR (搜索)-directed medicine discovery and development.